Be part of the knowledge.™

Rare and Orphan Diseases

389

LikeLikedUnlike

166-180 of 261

Patient Case: ATTRwt-CM Discovered Decades After Heart Transplant
Heart Matters
Patient Case: ATTRwt-CM Discovered Decades After Heart Transplant
- Lily Stern, MD
  Peer
Establishing D-VRd Efficacy for Transplant-Ineligible Multiple Myeloma
Project Oncology®
Establishing D-VRd Efficacy for Transplant-Ineligible Multiple Myeloma
Developments in Duchenne Muscular Dystrophy Care: Examining the Options
NeuroFrontiers
Developments in Duchenne Muscular Dystrophy Care: Examining the Options
Differentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
NeuroFrontiers
Differentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
- Maxwell H. Levy, MD
  Peer
Silent Brain Damage in ATTR-CM: Exploring Neurological Impacts
Spotlight On ATTR-CM
Silent Brain Damage in ATTR-CM: Exploring Neurological Impacts
Vutrisiran for ATTR-CM: Exploring an RNAi Therapeutic
Spotlight On ATTR-CM
Vutrisiran for ATTR-CM: Exploring an RNAi Therapeutic
advertisement
Exercise in Multiple Myeloma: Balancing Benefits and Safety
Project Oncology®
Exercise in Multiple Myeloma: Balancing Benefits and Safety
- Jens Hillengass, MD, PhD
  Peer
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
- Gil I. Wolfe MD, FAAN
  Peer
Challenges in DMD: Understanding the Height Factor
NeuroFrontiers
Challenges in DMD: Understanding the Height Factor
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
Project Oncology®
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
NKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
NeuroFrontiers
NKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
Diagnosing IgAN: The Importance of Early and Accurate Identification
Clinician's Roundtable
Diagnosing IgAN: The Importance of Early and Accurate Identification
- James Chevalier, MD
  Peer
advertisement
Investigating the Incidence of IgA Nephropathy Among Racial and Ethnic Groups
Clinician's Roundtable
Investigating the Incidence of IgA Nephropathy Among Racial and Ethnic Groups
- John Sim, MD
  Peer
Diagnosing Castleman Disease: Key Considerations
Project Oncology®
Diagnosing Castleman Disease: Key Considerations
- Mateo Bustamante
  Peer
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
Project Oncology®
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
- Joshua Brandstadter, MD, PhD, MSc
  Peer

Program Chapters

Segment Chapters

Playlist:

Recommended